Ascendis Pharma A (ASND) Change in Accured Expenses (2021 - 2024)

Ascendis Pharma A has disclosed Change in Accured Expenses across 4 years of filings, most recently posting -$8.5 million for Q4 2024.

• Change in Accured Expenses for Q4 2024 came in at -$8.5 million, down 160.59% year-over-year; the trailing twelve-month figure through Dec 2024 was $66.8 million (up 136.0% YoY), and the FY2024 annual result was $66.2 million, up 135.02% from the prior year.
• Change in Accured Expenses came in at -$8.5 million for Q4 2024 at Ascendis Pharma A, down from -$2.5 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $70.2 million in Q2 2024 to a low of -$8.5 million in Q4 2024.
• The 4-year median for Change in Accured Expenses is $1.8 million (2023), against an average of $7.9 million.
• Peak annual rise in Change in Accured Expenses reached 3826.88% in 2024, while the deepest fall reached 160.59% in 2024.
• Ascendis Pharma A's Change in Accured Expenses stood at $1.4 million in 2021, then declined by 10.96% to $1.2 million in 2022, then surged by 1059.34% to $14.1 million in 2023, then tumbled by 160.59% to -$8.5 million in 2024.
• The last three Change in Accured Expenses figures came in at -$8.5 million (Q4 2024), -$2.5 million (Q3 2024), and $70.2 million (Q2 2024), per Business Quant data.